Last kr77.40 SEK
Change Today +0.65 / 0.85%
Volume 1.5M
SOBI On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
OTC US
OTC US
As of 11:29 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Open
kr77.20
Previous Close
kr76.75
Day High
kr78.05
Day Low
kr76.60
52 Week High
07/3/14 - kr94.75
52 Week Low
10/28/13 - kr50.25
Market Cap
20.9B
Average Volume 10 Days
613.5K
EPS TTM
kr-1.38
Shares Outstanding
270.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, is engaged in the development, manufacture, and sale of pharmaceuticals primarily in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its principal products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. The company also offers various products, including Defibrotide, Erwinase, Ferriprox, and Willfact for used in the haematology therapeutic area; Aloxi, Cometriq, Kepivance, Megace, Multiferon, Removab, and Yondelis for use in the oncology therapeutic area; Cyanokit, Fomepizole, Ruconest, and ViperaTAb for use as emergency medicines and antidotes; and Betapred, Buronil, Mezavant, and Xiapex for the treatment of infectious diseases and specialty care. In addition, it develops rFVIIIFc, which is under Phase III clinical trials for the treatment of hemophilia A; rFIXFc that is under Phase III clinical trials to treat hemophilia B; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002, a complement C5 inhibitor, which is in Phase I clinical trials to treat genetic and metabolic diseases. The company has an agreement with Pfizer for the manufacture of drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A; and Biogen Idec for the development and commercialization of recombinant factor VIII and factor IX hemophilia programs. It also has a collaboration agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

569 Employees
Last Reported Date: 07/18/14

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr4.3M
Compensation as of Fiscal Year 2013.

swedish orphan biovitrum ab (SOBI) Key Developments

Swedish Orphan Biovitrum AB Reports Earnings Results for the Second Quarter and Six Month of 2014; Provides Earnings Guidance for 2014

Swedish Orphan Biovitrum AB reported earnings results for the second quarter and six month of 2014. For the quarter, total revenues were SEK 662.5 million against SEK 520.2 million, an increase of 27% with contribution from all areas of the portfolio. EBITA was SEK 86.3 million against SEK 37.8 million a year ago. EBIT was SEK 16.0 million against LBIT of SEK 31.9 million a year ago. Profit for the period was SEK 25.6 million against loss for the period of SEK 10.9 million a year ago. For the six months, total revenues were SEK 1,235.8 million against SEK 1,048.7 million a year ago. LBITA was SEK 201.5 million against EBITA of SEK 99.0 million a year ago. LBIT was SEK 342.0 million against SEK 35.3 million a year ago. Loss for the period was SEK 303.1 million against SEK 23.1 million a year ago. For 2014, the company continues to expect the company's total revenues for the full year to be in the range of SEK 2,300 to 2,500 million. The gross margin is expected to be in the range of 58-60 per cent. In addition, the operating costs are expected to increase as the company continues to prepare for the planned launch of the haemophilia programmes.

Swedish Orphan Biovitrum AB, Q2 2014 Earnings Call, Jul 18, 2014

Swedish Orphan Biovitrum AB, Q2 2014 Earnings Call, Jul 18, 2014

Swedish Orphan Biovitrum AB Files for EU Approval of Xiapex for Peyronie's Disease

Swedish Orphan Biovitrum AB has filed for an extension of the label for Xiapex with the European Medicines Agency to include the indication Peyronie's disease, a condition that involves the development of scar tissue on the shaft of the penis. The application follows approval from the U.S. Food and Drug Administration in December 2013. Xiapex is approved in Europe for the treatment of Dupuytren's contracture in adult patients with a palpable cord.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr77.40 SEK +0.65

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.28 EUR +0.164
Oxford Biomedica PLC 3.73 GBp 0.00
Veloxis Pharmaceuticals A/S kr1.90 DKK +0.02
View Industry Companies
 

Industry Analysis

SOBI

Industry Average

Valuation SOBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.0x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit www.biovitrum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.